Lipocine Corp - LPCN Quarterly EPS earnings growth

Lipocine Corporation - graphic logo of issuer LPCN

Lipocine Inc. has developed the innovative Oral-lyn system, which converts injectable hormones into convenient tablets. The anticipation of licensing agreements with industry behemoths following MASH trials remains a key driver. Patent protection and low demand elasticity ensure significant pricing power. The percentage change in quarterly EPS demonstrates management efficiency, where the value of 85.70 reflects the final status of profit dynamics.

Lipocine (LPCN) - Year-over-year earnings per share growth for the last twelve months from 07/04/2022 to 11/15/2026

Financial and market metric breakdowns for Lipocine Inc. (LPCN)

- share price and consensus valuation forecast:
Analysis of all company metrics:Lipocine Inc.
Manufactured product of Lipocine Corporation

This indicator measures the percentage change in net income per share between reporting periods, capturing the rate at which operating income is transformed into shareholder value. For Lipocine Inc. (LPCN), the quarterly net income per share trend reflects the efficiency of monetizing drug delivery licensing agreements, allowing investors to distinguish sustainable business growth from short-term speculative price spikes.

Competitors of Lipocine Inc. (LPCN)

ASND (Ascendis Pharma) - Year-over-year net earnings per share growth for the last 12 months|MDGL: Year-over-year earnings per share growth rate for the last twelve months|CORT (Corcept Therapeutics Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Rhythm Pharmaceuticals|Quarterly EPS earnings growth AKRO|Year-over-year earnings per share growth for the last twelve months MTSR (Metsera, Inc.)|Year-over-year earnings per share growth for the last twelve months moonlaketx.com MLTX|Crinetics Corp (CRNX) - Earnings per share growth in annualized terms for the last twelve months|NAMS - Year-over-year earnings per share growth for the last twelve months|SLNO: Year-over-year earnings per share growth for the last twelve months|FOLD: Quarterly EPS earnings growth|ETNB - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Agios Corp|Structure Corp (GPCR) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months mimedx.com (MDXG)|Year-over-year net earnings per share growth for the last 12 months rezolutebio.com RZLT|Year-over-year earnings per share growth for the last twelve months Lexicon Pharmaceuticals, Inc. LXRX|MBX Bio - Year-over-year earnings per share growth for the last twelve months|ALT: Year-over-year net earnings per share growth for the last 12 months|AARD - Quarterly EPS earnings growth|SGMT: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months BioAge Labs, Inc. (BIOA)|Year-over-year earnings per share growth for the last twelve months Biomea Fusion Inc|Year-over-year earnings per share growth for the last 12 months QNCX (Quince Therapeutics)|Year-over-year net earnings per share growth for the last 12 months GUTS (Fractyl Health)|Year-over-year earnings per share growth rate for the last twelve months VTVT|Agape ATP Corporation - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months PLUR|Synlogic Inc. - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months Matinas BioPharma Holdings, Inc. MTNB|SPRB: Quarterly EPS earnings growth|Galecto Corp - Year-over-year earnings per one share growth for the last 12 months|CTCX (carmellrx.com) - Quarterly EPS earnings growth|Quarterly EPS earnings growth lumos-pharma.com|Quarterly EPS earnings growth ONVO|Year-over-year net earnings per share growth for the last 12 months Radius Health RDUS